09 June 2000
Cellula rImmunology Markers Postransplantation Predictive of Long-Term Graft Outcome
Nancy L Reinsmoent, Annette M Jackson, Angelica DeOliveira, Arthur J Matas, Kristen Gillingham, Frances E WardAnn Transplant 2000; 5(2): 50-60 :: ID: 497526
Abstract
Identification of immune parameters that predict longterm graft outcome would aid in identifying those recipients at low versus high risk for immune complications and chronic rejection. Those recpients at low risk presumably could have their immunosuppression successfully lowered or even weaned thereby avoiding the many side effects of immunosuppressive therapy. Recipients who are at high risk for chronic rejection may benefit from changing or even increasing the immunosuppressive therapy. This article focuses on using cellular assays to monitor changes, quantitative and qualitative, in the T-cell recognition process during the posttransplant period, as a means to predict long-term graft outcome. We have focused our studies on the cellular immune parameter of donor antigen-specific hyporeactivity to determine whether we can predict long-term graft outcome for all solid organ recipients [1-8]...
Keywords: MLC, chronic rejection, donor-specific non-responsivness, limiting dilution
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






